HIF-1 inhibitors for cancer therapy

From gene expression to drug discovery

Research output: Contribution to journalArticle

Abstract

Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein composed of HIF-1α and HIF-1α subunits, which is activated in response to reduced O2 availability. HIF-1 transactivates genes encoding proteins that are involved in key aspects of the cancer phenotype, including cell immortalization and de-differentiation, stem cell maintenance, genetic instability, glucose uptake and metabolism, pH regulation, autocrine growth/survival, angiogenesis, invasion/metastasis, and resistance to chemotherapy. Increased HIF-1α levels, as determined by immunohistochemical analysis of tumor biopsy specimens, is associated with increased mortality in many human cancers. Drugs that inhibit HIF-1 activity and have anti-cancer effects in vivo have been identified and clinical trials are warranted to establish the contexts in which addition of such agents to therapy protocols will result in increased patient survival.

Original languageEnglish (US)
Pages (from-to)3839-3843
Number of pages5
JournalCurrent Pharmaceutical Design
Volume15
Issue number33
DOIs
StatePublished - Nov 2009

Fingerprint

Hypoxia-Inducible Factor 1
Drug Discovery
Gene Expression
Neoplasms
Therapeutics
Survival
Proteins
Stem Cells
Maintenance
Clinical Trials
Neoplasm Metastasis
Phenotype
Biopsy
Glucose
Drug Therapy
Mortality
Growth
Pharmaceutical Preparations

Keywords

  • Angiogenesis
  • Cancer
  • Chemotherapy
  • Hypoxia-inducible factor
  • Invasion
  • Metastasis
  • Metronomic therapy
  • Oxygen

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

HIF-1 inhibitors for cancer therapy : From gene expression to drug discovery. / Semenza, Gregg L.

In: Current Pharmaceutical Design, Vol. 15, No. 33, 11.2009, p. 3839-3843.

Research output: Contribution to journalArticle

@article{fb36dd7f4ac54b44a3ee83e4a0cd09c1,
title = "HIF-1 inhibitors for cancer therapy: From gene expression to drug discovery",
abstract = "Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein composed of HIF-1α and HIF-1α subunits, which is activated in response to reduced O2 availability. HIF-1 transactivates genes encoding proteins that are involved in key aspects of the cancer phenotype, including cell immortalization and de-differentiation, stem cell maintenance, genetic instability, glucose uptake and metabolism, pH regulation, autocrine growth/survival, angiogenesis, invasion/metastasis, and resistance to chemotherapy. Increased HIF-1α levels, as determined by immunohistochemical analysis of tumor biopsy specimens, is associated with increased mortality in many human cancers. Drugs that inhibit HIF-1 activity and have anti-cancer effects in vivo have been identified and clinical trials are warranted to establish the contexts in which addition of such agents to therapy protocols will result in increased patient survival.",
keywords = "Angiogenesis, Cancer, Chemotherapy, Hypoxia-inducible factor, Invasion, Metastasis, Metronomic therapy, Oxygen",
author = "Semenza, {Gregg L}",
year = "2009",
month = "11",
doi = "10.2174/138161209789649402",
language = "English (US)",
volume = "15",
pages = "3839--3843",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "33",

}

TY - JOUR

T1 - HIF-1 inhibitors for cancer therapy

T2 - From gene expression to drug discovery

AU - Semenza, Gregg L

PY - 2009/11

Y1 - 2009/11

N2 - Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein composed of HIF-1α and HIF-1α subunits, which is activated in response to reduced O2 availability. HIF-1 transactivates genes encoding proteins that are involved in key aspects of the cancer phenotype, including cell immortalization and de-differentiation, stem cell maintenance, genetic instability, glucose uptake and metabolism, pH regulation, autocrine growth/survival, angiogenesis, invasion/metastasis, and resistance to chemotherapy. Increased HIF-1α levels, as determined by immunohistochemical analysis of tumor biopsy specimens, is associated with increased mortality in many human cancers. Drugs that inhibit HIF-1 activity and have anti-cancer effects in vivo have been identified and clinical trials are warranted to establish the contexts in which addition of such agents to therapy protocols will result in increased patient survival.

AB - Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein composed of HIF-1α and HIF-1α subunits, which is activated in response to reduced O2 availability. HIF-1 transactivates genes encoding proteins that are involved in key aspects of the cancer phenotype, including cell immortalization and de-differentiation, stem cell maintenance, genetic instability, glucose uptake and metabolism, pH regulation, autocrine growth/survival, angiogenesis, invasion/metastasis, and resistance to chemotherapy. Increased HIF-1α levels, as determined by immunohistochemical analysis of tumor biopsy specimens, is associated with increased mortality in many human cancers. Drugs that inhibit HIF-1 activity and have anti-cancer effects in vivo have been identified and clinical trials are warranted to establish the contexts in which addition of such agents to therapy protocols will result in increased patient survival.

KW - Angiogenesis

KW - Cancer

KW - Chemotherapy

KW - Hypoxia-inducible factor

KW - Invasion

KW - Metastasis

KW - Metronomic therapy

KW - Oxygen

UR - http://www.scopus.com/inward/record.url?scp=70649088040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70649088040&partnerID=8YFLogxK

U2 - 10.2174/138161209789649402

DO - 10.2174/138161209789649402

M3 - Article

VL - 15

SP - 3839

EP - 3843

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 33

ER -